# A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors

> **NCT06399757** · PHASE1,PHASE2 · RECRUITING · sponsor: **Apollo Therapeutics Ltd** · enrollment: 100 (estimated)

## Conditions studied

- Colorectal Cancer
- Cholangiocarcinoma
- Appendiceal Adenocarcinoma
- Pancreatic Adenocarcinoma
- Gastric Adenocarcinoma
- Endometrial Adenocarcinoma
- Triple Negative Breast Cancer
- Ovarian Cancer
- Prostate Cancer

## Interventions

- **DRUG:** APL-5125

## Key facts

- **NCT ID:** NCT06399757
- **Lead sponsor:** Apollo Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-18
- **Primary completion:** 2027-04
- **Final completion:** 2027-05
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06399757

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06399757, "A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06399757. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*